P53 Gene as a Promising Biomarker and Potential Target for the Early Diagnosis of Reproductive Cancers
- PMID: 38864057
- PMCID: PMC11165294
- DOI: 10.7759/cureus.60125
P53 Gene as a Promising Biomarker and Potential Target for the Early Diagnosis of Reproductive Cancers
Abstract
One of the crucial aspects of cancer research is diagnosis with specificity and accuracy. Early cancer detection mostly helps make appropriate decisions regarding treatment and metastasis. The well-studied transcription factor tumor suppressor protein p53 is essential for maintaining genetic integrity. p53 is a key tumor suppressor that recognizes the carcinogenic biological pathways and eradicates them by apoptosis. A wide range of carcinomas, especially gynecological such as ovarian, cervical, and endometrial cancers, frequently undergo TP53 gene mutations. This study evaluates the potential of the p53 gene as a biological marker for the diagnosis of reproductive system neoplasms. Immunohistochemistry of p53 is rapid, easy to accomplish, cost-effective, and preferred by pathologists as a surrogate for the analysis of TP53 mutation. Thus, this review lays a groundwork for future efforts to develop techniques using p53 for the early diagnosis of cancer.
Keywords: biomarker; cancer; p53 gene; reproductive cancer; tumor suppressor gene.
Copyright © 2024, K et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures



Similar articles
-
The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.Int J Gynecol Pathol. 2021 Jan;40(1):32-40. doi: 10.1097/PGP.0000000000000725. Int J Gynecol Pathol. 2021. PMID: 33290354 Review.
-
Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.Mod Pathol. 2011 Sep;24(9):1248-53. doi: 10.1038/modpathol.2011.85. Epub 2011 May 6. Mod Pathol. 2011. PMID: 21552211
-
Analysis of full coding sequence of the TP53 gene in invasive vulvar cancers: Implications for therapy.Gynecol Oncol. 2017 Aug;146(2):314-318. doi: 10.1016/j.ygyno.2017.05.018. Epub 2017 May 17. Gynecol Oncol. 2017. PMID: 28527674
-
Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.Pathology. 2024 Mar;56(2):214-227. doi: 10.1016/j.pathol.2023.10.013. Epub 2023 Dec 12. Pathology. 2024. PMID: 38212229 Review.
-
Cytoplasmic Pattern p53 Immunoexpression in Pelvic and Endometrial Carcinomas With TP53 Mutation Involving Nuclear Localization Domains: An Uncommon But Potential Diagnostic Pitfall With Clinical Implications.Am J Surg Pathol. 2021 Nov 1;45(11):1441-1451. doi: 10.1097/PAS.0000000000001713. Am J Surg Pathol. 2021. PMID: 33899789
Cited by
-
Identification of prognostic biomarkers for endometrioid endometrial carcinoma based on the miRNA and mRNA co-expression network regulated by estradiol.Clinics (Sao Paulo). 2025 May 3;80:100672. doi: 10.1016/j.clinsp.2025.100672. eCollection 2025. Clinics (Sao Paulo). 2025. PMID: 40319860 Free PMC article.
-
Modulating the p53-MDM2 pathway: the therapeutic potential of natural compounds in cancer treatment.EXCLI J. 2024 Nov 22;23:1397-1439. doi: 10.17179/excli2024-7791. eCollection 2024. EXCLI J. 2024. PMID: 39764218 Free PMC article. Review.
References
-
- Cancer statistics, 2013. Siegel R, Naishadham D, Jemal A. CA Cancer J Clin. 2013;63:11–30. - PubMed
-
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. CA Cancer J Clin. 2021;71:209–249. - PubMed
-
- Cancer biomarkers: knowing the present and predicting the future. Chatterjee SK, Zetter BR. Future Oncol. 2005;1:37–50. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous